Nature Medicine
This journal encompasses original research ranging from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative technologies aimed at improving human health.
Composition of the gut microbiome is associated with response and toxicity following anti-CD19 CAR T cell therapy
The intestinal microbiome is associated with clinical outcomes after anti-CD19 CAR T cell therapy in patients with B-cell malignancies.
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer patients: the NABUCCO trial
This blog reflects on the journey that led to the publication of our preoperative combination immunotherapy study in Nature Medicine.
Zero Childhood Cancer – an Australian national precision medicine program for high-risk pediatric cancer
What value does deciphering the whole genome hold for guiding clinical care of children with high-risk cancer? Does it provide more accurate diagnoses, more treatment options, better risk stratification? Can it be analyzed fast enough to have real-time clinical impact?
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
In the November issue of Nature Medicine we describe the development of a first-in-class inhibitor of CLCF1 signaling and its effectiveness in several precllinical models of lung adenocarcinoma
